Fluconazole and Als3 Polypeptide for Recurrent VVC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vulvovaginal candidiasis, particularly recurrent vulvovaginal candidiasis (RVVC), are ineffective in providing a long-term cure, with high recurrence rates and significant economic and quality-of-life impacts.
Innovation Solution
Administering an effective amount of the antifungal agent fluconazole in combination with an immunogenic Als3 polypeptide, either as a vaccine composition with an adjuvant or without, to reduce the recurrence of VVC by inducing an immune response against Candida albicans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If azole medications are used to treat VVC, then fungal cell wall metabolism is inhibited, but long-term cure is difficult to achieve with high recurrence rates
Solution Approach 1:
The patent combines antifungal medications with immunogenic Als3 polypeptide in a single treatment regimen. This merging of direct antifungal action with immune system activation creates a dual-mechanism treatment that addresses both immediate infection and long-term prevention, resolving the contradiction between short-term effectiveness and long-term durability.
Solution Approach 2:
The Als3 polypeptide acts as a preliminary immune priming agent that prepares the immune system to recognize and combat Candida albicans before recurrence occurs. This preliminary immunization establishes long-term protective immunity that persists beyond the immediate antifungal treatment effect, extending the duration of cure.
2Duration of action of stationary object
If maintenance fluconazole therapy is prescribed for RVVC, then recurrence is delayed, but long-term cure remains difficult to find
Solution Approach 1:
The patent merges maintenance fluconazole therapy with Als3 polypeptide immunization. The antifungal agent maintains suppression of active infection while the immunogenic polypeptide builds reliable long-term immune protection, transforming temporary delay of recurrence into reliable long-term cure through dual-mechanism action.
Solution Approach 2:
The Als3 polypeptide enables the immune system to serve itself by generating auto-antibodies that automatically recognize and neutralize Candida albicans upon recurrence. This self-service immune mechanism reduces dependence on continuous antifungal medication, improving cure reliability while maintaining extended duration of protection.
3Object-affected harmful factors
If antifungal agents are used alone, then symptomatic infection is treated, but prevention of recurrence is insufficient
Solution Approach 1:
The patent merges symptomatic treatment with preventive immunization in a single integrated therapy. The antifungal agent addresses active infection symptoms while the Als3 polypeptide simultaneously establishes immune protection against future recurrence, resolving the contradiction between treating current symptoms and preventing future episodes.
Solution Approach 2:
The patent converts the harmful presence of Candida albicans into a beneficial immunogenic stimulus. By using the Als3 polypeptide from the pathogen itself as the vaccine antigen, the treatment transforms the enemy's molecular structure into a tool for creating protective immunity, thereby converting the harm of infection into the benefit of long-term prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined use of fluconazole and Als3 polypeptide significantly reduces the recurrence of VVC, providing a more effective treatment option by enhancing the immune system's ability to combat Candida albicans, thereby improving clinical outcomes and reducing the frequency of episodes.
Implementation Method 1
administering an immunogenic amount of an Als3 polypeptide to the subject, to reduce VVC in the subject
Data Source
AI summary
The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.